Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Amg 513

Phase 1

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cardiometabolic DiseaseRecruiting

Cardiometabolic DiseasePhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Cardiometabolic Disease

NCT06585462

Clinical

Trials by Indication[1]

Cardiometabolic Disease1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity

Recruiting· Amgen logo

Amgen·Phase 1·NCT06585462·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amg 513. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Amg 513. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Amgen

Related News